Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVAX stock price vs STZ: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STZ's multiple
Needs STZ P/E.
Implied fair value · at NVAX's multiple
Needs EPS (TTM), NVAX P/E.
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NVAX FY 2025 (ended Dec 31, 2025) · STZ FY 2026 (ended Feb 28, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NOVAVAX INC · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
CONSTELLATION BRANDS, INC. · implied price per share
A valid share-count denominator is required for the selected valuation policy.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
-2.76x
1.35x
Net debt / EBITDA
Leverage against operating earnings
-0.84x
3.51x
Cash and equivalents
Liquid reserves on the balance sheet
$735.08M
$102.40M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
NVAX vs MRNA
BioNTech SE
NVAX vs BNTX
Emergent BioSolutions Inc.
NVAX vs EBS
ASTRAZENECA PLC
NVAX vs AZN
GSK plc
NVAX vs GSK
MOLSON COORS BEVERAGE CO
NVAX vs TAP
BOSTON BEER CO INC
NVAX vs SAM
DIAGEO PLC
NVAX vs DEO
Monster Beverage Corp
NVAX vs MNST
BROWN FORMAN CORP
NVAX vs BF-A
$353.17M
$10.90B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
